INTRODUCTION
============

A radical prostatectomy is the most common primary treatment for clinically localized prostate cancer ([@B1]). In terms of cancer control, a radical prostatectomy gives good results when the cancer is confined within the prostate ([@B2]). Nevertheless, approximately one third of patients will experience biochemical recurrence as shown by prostate-specific antigen (PSA) elevation within 10 yr after a prostatectomy ([@B3], [@B4], [@B5], [@B6]). An unfavorable pathology such as extraprostatic disease is detected at prostatectomy in 52% of the patients and is associated with biochemical recurrence ([@B7], [@B8], [@B9], [@B10]). Consequently, proper risk stratification after prostatectomy is important for individualized treatment and patient counseling.

To facilitate risk stratification, many nomograms and predictors have been developed. The Cancer of the Prostate Risk Assessment (CAPRA) score is one of them. After the CAPRA score was introduced for preoperative prostate cancer risk stratification, its validity was assessed and relatively good predictability was found ([@B11], [@B12], [@B13], [@B14], [@B15], [@B16], [@B17], [@B18], [@B19]). To improve the accuracy of prediction, the pathology findings were added which was named as CAPRA-S score was developed by The University of California, San Francisco ([@B13]). Recently, its external validity was studied using the Shared Equal Access Regional Cancer Hospital (SEARCH) database and the results validated its effectiveness and ability to predict biochemical recurrence following surgery ([@B20]). However, no study has compared the validity of the CAPRA-S score with preoperative predictors in Asian populations.

Therefore, this study examined the validity of the CAPRA-S score in our institution and its superiority to other preoperative predictors, especially the CAPRA score, which has been validated in large, multi-institutional and head-to-head studies ([@B17], [@B20]).

MATERIALS AND METHODS
=====================

A total of 130 patients who underwent prostatectomy between 2008 and 2013 by a single surgeon as analyzed retrospectively. The sum of scores of each variables were calculated for CAPRA-S score and CAPRA score. The CAPRA-S scores were calculated using the variables and each scores described in [Table 1](#T1){ref-type="table"} ([@B13]) and the CAPRA scores were calculated in the same manner with only preoperative variables ([@B21]). Fifteen patients were excluded from the CAPRA score group because there were no information about percent positive biopsies. The patients were divided into two groups: each score group and a three-risk level group model (low, intermediate, and high risk). The each score group model means which was stratifying by CAPRA score sum from 0 to 10 point. And of the three-risk group model, low risk groups were 0-2 point and intermediate risk groups were 3-5 point, high risk groups were above 6 point of CAPRA-S score sum ([Table 2](#T2){ref-type="table"}). Biochemical recurrence after radical prostatectomy was defined as two consecutive PSA values≥0.2 ng/mL at any time postoperatively or any additional treatment more than 6 months after the prostatectomy.

The ability of the CAPRA-S score to predict the 3- and 5-yr progression-free probabilities at our institution was examined. In addition, the 5-yr progression-free probabilities of each score group and the three risk groups were analyzed using Kaplan-Meier analysis and the Cox proportional hazards regression. Finally, the prediction probability of the CAPRA-S score and preoperative CAPRA score were compared through logistic regression analysis with calculated concordance index (c-index) and decision curve analysis. The statistical analysis was supported by Clinical Trail Center, Inje University Busan Paik Hospital.

Ethics statement
----------------

This study protocol was reviewed and approved by the institutional review board of the Inje University Busan Paik Hospital (IRB number 13-223). Informed consent was waived due to the retrospective design of the study.

RESULTS
=======

Recurrence occurred in 13.8% of the 130 patients at a median of 13 months (SD 12.1). There was wide distribution of CAPRA-S scores and 25.4% of the patients had scores\>6; these constituted the high-risk group ([Table 2](#T2){ref-type="table"}).

The 5-yr progression-free probabilities for each CAPRA-S score group and the three risk groups are shown in [Table 3](#T3){ref-type="table"} and illustrated in [Fig. 1](#F1){ref-type="fig"} with Kaplan-Meier curves. For each CAPRA-S score, the progression of disease increased with the risk, although this trend was not significant and had no consistency. Nevertheless, the results from the three-risk-group model showed statistical significance in terms of disease progression with increasing risk. Especially in the high-risk group (CAPRA-S score\>6), the 5-yr progression-free probability was 56.9% and its hazard ratio was 13.1 (*P*=0.014; [Fig. 1B](#F1){ref-type="fig"}).

The CAPRA-S score had a higher c-index than the CAPRA score. Except for the 3-yr progression-free probability, the prediction ability of the CAPRA-S score was superior ([Table 4](#T4){ref-type="table"}). The c-index of each CAPRA-S score group for the 5-yr progression-free probabilities was 0.80, while that of each CAPRA score group was 0.77 (*P*=0.041). In the three-risk-group model of the CAPRA-S score, the 3- and 5-yr progression-free probabilities were significantly higher than for the CAPRA score. The c-index for the 3- and 5-yr progression-free probabilities of the CAPRA-S score was 0.74 and 0.77, respectively, while that of the CAPRA score was 0.70 and 0.71 (*P*\<0.001).

Finally, the decision curve analysis comparing the CAPRA-S and CAPRA scores indicated a better net benefit of appropriately identifying patients for adjuvant therapy with both scoring systems ([Fig. 2](#F2){ref-type="fig"}). Although the CAPRA-S score did not cover all of the threshold probabilities, it resulted in a more ideal curve than the CAPRA score and both curves did not locate below of the reference curves.

DISCUSSION
==========

The CAPRA score has been validated externally in the US and European multi-institutional studies with high accuracy with c-indexes ranging from 0.66 to 0.81 ([@B12], [@B16], [@B17], [@B18], [@B19]). Another study demonstrated that it predicted recurrence with the PSA doubling time, metastasis, and cancer-specific mortality ([@B22], [@B23]). Its superiority over other nomograms has been demonstrated ([@B17], [@B24]). The pathology results after radical prostatectomy facilitate prediction of biochemical recurrence and disease progression, so the CAPRA-S score should be better than the CAPRA score for deciding which additional treatments might benefit selected patients ([@B13], [@B25], [@B26], [@B27]).

The c-index for the CAPRA-S score in a European multi-institutional study was 0.73 and was higher than for the Stephenson nomogram ([@B20]). In our study, the c-index of the CAPRA-S score for the 3- and 5-yr progression-free probabilities was 0.76 and 0.80, respectively. The c-index of the CAPRA-S three risk groups was 0.74 and 0.77, respectively. The progression-free probabilities for each CAPRA-S score was relatively higher in this study compared with the SEARCH and Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) data. We postulated that this result was influenced by the low rate of biochemical recurrences in our patients (13.8%) compared with the SEARCH (33%) and CaPSURE (16%) data. In addition, the small number of patients in our study and the unevenly distributed characteristics might have influenced the results. Also the present study was not a prospective study. Therefore, our study was not representative and had several limitations. Nevertheless, the validity of the CAPRA-S score in our study was clear and its usefulness convincing.

Comparing with preoperative nomograms, the CAPRA score was superior ([@B17], [@B24]). We also compared the CAPRA and CAPRA-S scores, which were constructed from similar items and patients, and examined whether the performance of CAPRA-S score was more accurate. For the three risk groups, the CAPRA-S score had significantly (*P*\<0.001) greater predictive ability for the 3- and 5-yr progression-free probabilities (0.74 and 0.77, respectively) than did the CAPRA score (0.70 and 0.71, respectively). In the decision curve analysis, both the CAPRA and CAPRA-S scores had a better net benefit of appropriately identifying patients for adjuvant therapy. The CAPRA-S score traced a more ideal curve than the CAPRA score, as no point below the reference lines was seen. However, neither was clearly superior.

Despite the high accuracy of the CAPRA-S score for predicting the progression of prostate cancer after prostatectomy, Korean results, including our study, gave different survival curves and progression-free probabilities compared to results using SEARCH and CaPSURE data. The first Korean study of the CAPRA-S score found that the survival curves for the progression-free probabilities were inconsistent ([@B28]). We also obtained similar results for inconsistence about survival curve of progression-free probabilities using CAPRA-S score. We must consider the baseline characteristics of the patients. In the two Korean studies including present study, high-risk prostate patients comprised 35.8% and 25.4% of the total, compared 17% for the SEARCH data and for 6.5% CaPSURE ([@B13], [@B20], [@B28]). Although the Korean studies enrolled fewer patients, the race- and nation-specific characteristics of prostate cancer should be considered to develop a more accurate prediction model. Koreans with prostate cancer in whom a radical prostatectomy is indicated had poorer characteristics than Americans ([@B29]). It is important that a more specific prediction model in terms of race and nation be developed. Just as no nomograms have shown absolute prediction ability, the CAPRA-S score might also need continuous correction.

Although biochemical recurrence or disease progression does not correlate with the mortality of prostate cancer directly, adjuvant therapy might be required given poor pathology results. As the decision curve analysis showed, the CAPRA-S score should be able to stratify the patients who need adjuvant therapy after radical prostatectomy with good predictability more easily than CAPRA score. A large-scale study should examine the performance of the CAPRA-S score in stratifying patients who need adjuvant therapy.

Conclusively, the CAPRA-S score, which includes pathology results, is a useful predictor of prostate cancer progression after radical prostatectomy compared with the CAPRA score. It may help clinicians and patients to decide on adjuvant therapy after surgery. After further revision according to race or national characteristics, the CAPRA-S score might also be useful in other countries with an increasing incidence of prostate cancer, as in Korea.
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Distribution of the data according to the CAPRA-S and CAPRA scores
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Distribution of patients according the CAPRA-S score and three-risk-group model
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The 5-yr progression-free probabilities for the CAPRA-S score groups and three-risk-group model
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HR, hazard ratio; CI, confidence interval; PGPs, progression-free probabilities.

###### 

Comparison of the c-index for progression-free probabilities using logistic regression between the CAPRA-S and CAPRA scores
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HR, hazrard ratio; CI, confidence interval; CAPRA, cancer of the prostate risk assessment.
